After ACTA, EU needs new tools to protect EU intellectual property rights

9 June 2015
eu-european-union-flag

After the Anti-Counterfeiting Trade Agreement (ACTA), the European Union needs better tools to protect EU intellectual property in third countries, say Members of the European Parliament (MEPs) in a resolution voted today.

They asked the European Commission to look into appropriate means and methods to this end. In a separate resolution, also voted on Tuesday, they advocate assessing and adjusting intra-EU rules to combat online breaches of intellectual property rights (IPRs).

The "commercial nature of many IPR infringements" and the "growing involvement of organized crime" pose a serious threat to creativity and innovation, which are the EU's key assets in the global market say MEPs, in a resolution drafted by Maria Alessia Mosca (S&D, Italy) and approved on Tuesday by 521 votes to 164 with 17 abstentions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical